ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

Bousquet, Jean; Jutel, Marek; Akdiş, Cezmi A.; Klimek, Ludger; Pfaar, Oliver; Nadeau, Kari; Eiwegger, Thomas; Bedbrook, Anna; Ansotegui, Ignacio J.; Antó, Josep M; Bachert, Claus; Bateman, Eric D.; Bennoor, Kazi Saifuddin; Berghea, Elena Camelia; Bergmann, Karl‐Christian; Blain, Hubert; Bonini, Matteo; Bosnic‐Anticevich, Sinthia; Boulet, Louis‐Philippe; Brussino, Luisa; Buhl, Roland; Camargos, Paulo Augusto Moreira; Canonica, Giorgio Walter; Cardona, Victòria; Casale, Thomas B.; Chinthrajah, Sharon; Akdiş, Mübeccel; Chivato, T.; Christoff, George; Cruz, Álvaro A.; Czarlewski, Wienczyslawa; Giacco, Stefano Del; Du, Hui; El‐Gamal, Yehia; Fokkens, Wytske J.; Fonseca, João; Gao, Yuwei; Gaga, Mina; Gemicioğlu, Bilun; Gotua, Maia; Haahtela, Tari; Halpin, David; Hamelmann, Eckard; Hoffmann‐Sommergruber, Karin; Humbert, Marc; Ilina, N I; Ivancevich, Juan‐Carlos; Joos, Guy; Khaitov, Musa; Kirenga, Bruce; Knol, Edward F.; Ko, Fanny W.; Koskinen, Seppo; Kowalski, Marek L.; Kraxner, Helga; Kudlаy, D.А.; Kuna, Piotr; Kupczyk, Maciej; Kvedariene, Violeta; Latiff, Amir Hamzah Abdul; Le, Lan T.; Levin, Michael; Larenas‐Linnemann, Désirée; Louis, Renaud; Masjedi, Mohammad Reza; Melén, Erik; Florin, Mihaltan; Milenković, Branislava; Mohammad, Yousser; Morais‐Almeida, Mário; Mullol, Joaquim; Намазова, Л.С.; Neffen, Hugo; Nunes, Elisabete; O’Byrne, Paul M.; O’Hehir, Robyn E; O’Mahony, Liam; Ohta, Ken; Okamoto, Yoshitaka; Onorato, Gabrielle L.; Panzner, Petr; Papadopoulos, Nikolaos G.; Passalacqua, Giovanni; Patella, Vincenzo; Pawankar, Ruby; Pham‐Thi, N.; Pigearias, Bernard; Popov, Todor A.; Puggioni, Francesca; Regateiro, Frederico S.; Rolla, Giovanni; Rottem, Menachem; Samoliński, Bolesław; Sastre, Joaquı́n; Schwarze, Jürgen; Sheikh, Aziz; Scichilone, Nicola; Soto-Quirós, Manuel E.; Manuel, Soto‐Martinez; Sova, Milan; Nicola, Stefania; Stelmach, Rafaël; Suppli‐Ulrik, Charlotte; Taborda-Barata, Luís; To, Teresa; Tomazic, Peter‐Valentin; Toppila‐Salmi, Sanna; Tsiligianni, Ioanna; Usmani, Omar; Valiulis, Arūnas; Ventura, Maria Teresa; Viegi, Giovanni; Vontetsianos, T.; Wang, De Yun; Williams, Siân; Wong, Gary; Yorgancıoğlu, Arzu; Mario, Zernotti; Zidarn, Mihaela; Zuberbier, Torsten; Agache, Ioana

doi:10.1111/all.14471

Cited by 72 publications

(115 citation statements)

References 19 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…All of the participants reported that they took precautions for infection prevention and control at their hospitals. Participants were using national and international societies' guidelines and online services such as those of the TNSACI, the European Academy of Allergy and Clinical Immunology (EAACI), the World Allergy Organization (WAO), and the Global Initiative for Asthma (GINA) as resources for COVID-19 [ 1 , 2 , 3 , 4 , 5 ]. Telemedicine was used for the management of asthma (73%), allergic rhinitis (53%), atopic dermatitis (51%), chronic urticaria/angioedema (59%), drug hypersensitivity (45%), food allergy (48%), venom allergy (30%), anaphylaxis (22%), and hereditary angioedema (28%).…”

Section: Resultsmentioning

confidence: 99%

Change in Allergy Practice during the COVID-19 Pandemic

Öztürk

Baççıoğlu

Soyer

et al. 2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: International guidelines in asthma and allergy has been updated for COVID-19 pandemic and pandemic has caused dramatic changes in allergy and immunology services. However, it is not known whether specialty-specific recommendations for COVID-19 are followed by allergists. Objectives: By conducting this study, we aimed to determine the attitudes and experiences of adult/pediatric allergists on allergy management during COVID-19. Method: We used a 20-question survey to elicit data from allergists (residents and pediatric and adult allergists registered to the Turkish National Society of Allergy and Clinical Immunology) across Turkey via e-mail. We analyzed the data statistically for frequency distributions and descriptive analysis. Results: A total of 183 allergists participated in the survey. Telemedicine was used for management of asthma (73%), allergic rhinitis (53%), atopic dermatitis (51%), chronic urticaria/angioedema (59%), drug hypersensitivity (45%), food allergy (48%), venom allergy (30%), anaphylaxis (22%), and hereditary angioedema (28%). Thirty-one percent of the respondents discontinued subcutaneous immunotherapy (SCIT) during the COVID-19 pandemic. Thirty-four percent of the physicians reported interruption of systemic steroid use in asthma patients, and 25% of the respondents discontinued biological therapy. Conclusions: Allergists in Turkey have been using telemedicine at a high rate during the COVID-19 pandemic for asthma and rhinitis. The continuation rate of SCIT was low while the discontinuation rate of biologicals and systemic steroid use in asthma was high in Turkey.Our study results and learning from the experiences of other countries and specialties may help to optimize allergy practice and compatibility with international guidelines.

show abstract

Section: Resultsmentioning

confidence: 99%

Change in Allergy Practice during the COVID-19 Pandemic

Öztürk

Baççıoğlu

Soyer

et al. 2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Therefore, SARS-CoV-2 can easily reach the lower airways by binding to ACE2 receptors in the bronchi cells and type II alveolar cells, and may aggravate asthma. However, the ARIA-EAACI statement has reported that asthma does not seem to be a risk factor for severe COVID-19 (7).…”

Section: Coronaviruses and Asthma Exacerbationsmentioning

confidence: 99%

“…The Centers for Disease Control and Prevention (CDC) has stated that subjects with moderate to severe asthma may have an increased risk for COVID-19 and the infection may lead to an asthma attack, pneumonia, or acute respiratory disease (6). However, the ARIA-EAACI statement on Asthma and COVID-19 has reported that asthma does not seem to be a risk factor for severe COVID-19 (7). Only asthma patients using oral corticosteroids were defined as a risky group for COVID-19 or severe asthma flare-ups (7).…”

mentioning

confidence: 99%

“…However, the ARIA-EAACI statement on Asthma and COVID-19 has reported that asthma does not seem to be a risk factor for severe COVID-19 (7). Only asthma patients using oral corticosteroids were defined as a risky group for COVID-19 or severe asthma flare-ups (7). This review aims to summarize the updated data about the association between viral infections and asthma exacerbations including COVID infection and management of asthma flare-ups during the COVID pandemic, based on recommended asthma guidelines.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Role of SARS-CoV-2 in Asthma Exacerbations

Öztürk¹,

Bavbek²

2020

Asthma Allergy Immunol

View full text Add to dashboard Cite

Asthma is one of the most common chronic respiratory diseases in the world and there is great concern about the effect of COVID-19 infection on asthma severity and control. Although the link between asthma and COVID-19 infection remains to be determined, available data indicate that asthma does not seem to be a risk factor for severe COVID-19. This review aims to summarize the updated data about the association between viral infections and asthma exacerbations including COVID infection and management of asthma flare-ups during the COVID pandemic, based on the recommended asthma guidelines.

show abstract

“…Sputum cells among patients with asthma may give a risk for COVID-19 morbidity [15]. The prevalence of COVID-19 among asthmatic patient was 9% [16]. Yet, there is no pooled result of the COVID-19 burden, admission and outcome among asthmatic patients in Africa.…”

Section: Introductionmentioning

confidence: 99%

The burden, admission, and outcomes of COVID-19 among asthmatic patients in Africa: protocol for a systematic review and meta-analysis

Hailay

Aberhe

Zereabruk

et al. 2020

asthma res and pract

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 outbreak is the first reported case in Wuhan, China in December 2019 and suddenly became a major global health concern. According to the European Centre for Disease Prevention and Control, on August 4, 2020 the reported cases of coronavirus disease 2019 were 18,456,952 cases worldwide, 11,691, 229 recovered with 697,719 deaths. Evidence on Burden, admission and outcome of Coronavirus Disease in 2019 among Asthmatic patients has not been published in Africa. This research protocol will, therefore, be driven to conduct systematic review and meta-analysis of the Coronavirus Disease in 2019 burden, admission and outcome among Asthmatic patients in Africa. Methods: All observational studies among Asthmatic patients in Africa and written without language limitation will be included. A search technique was applied using Databases (PubMed / MEDLINE, EMBASE, HINARI, Cochrane Library, World Health Organization COVID-19 database, Africa Wide Knowledge and Web of Science). Two independent authors carried out data extraction and assess the risk of bias using a predetermined and structured method of data collection. We will use random-effects to estimate the overall pooled burden, admission and outcome of COVID-19 Asthmatic patients in Africa. To assess possible publication bias, funnel plot test and Egger's test methods will be used. This systematic and meta-analysis review protocol will be reported based on the Preferred Reporting Items for Systematic reviews and Meta-Analysis protocol guidelines. Discussion: The description will be used to show the COVID-19 distribution data by interest variables such as residence, setting, and person-level characteristics. The findings of this review will notify health care professionals about the burden, admission and outcome of COVID − 19 in asthmatic patient, while providing evidence to bring about the requisite improvements in clinical practice for asthmatic patients. Systematic review registration: This review is registered in the PROSPERO International Prospective Register of Systematic reviews with the registration number of CRD42020202049.

show abstract

ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 72 publications

References 19 publications

Change in Allergy Practice during the COVID-19 Pandemic

Change in Allergy Practice during the COVID-19 Pandemic

Role of SARS-CoV-2 in Asthma Exacerbations

The burden, admission, and outcomes of COVID-19 among asthmatic patients in Africa: protocol for a systematic review and meta-analysis

Contact Info

Product

Resources

About